ReNerve builds sales momentum as NervAlign study nears completion

Revenue growth meets a wider commercial push

ReNerve Ltd (ASX:RNV) is presenting a more ambitious commercial picture at its October 2026 annual general meeting, with annual revenue up 88% and quarterly sales more than 50% higher than the previous quarter. The presentation does not provide a full income statement, but the sales trajectory gives the nerve-repair and wound-care company a stronger platform as it expands its product range.

ReNerve reported cash of $1.48 million at 30 June and said it signed a $5 million funding facility with RiverFort in early July. The presentation does not disclose the facility’s drawdown status or detailed terms, leaving the effect on near-term liquidity and potential dilution unclear. It does, however, frame the funding as part of a plan to build sales capacity and bring additional products to market.

US distribution network reaches 25 partners

The company says it now has 25 US distributors, two direct salespeople and logistics, warehousing and invoicing infrastructure in place. Its commercial focus spans hand and upper-extremity surgery, plastics and reconstruction, lower extremity, breast, spine, and head and neck procedures. ReNerve says all call points use its product range, a strategy intended to support bundled hospital sales rather than relying on a single nerve-repair product.

Internationally, the presentation identifies active or developing opportunities across Hong Kong, India, the Philippines, Malaysia, Thailand and Indonesia. It cites initial orders or sales in some markets, hospital approvals in others, and discussions with local distribution partners. Those statements indicate a broadening footprint, but the presentation does not quantify the revenue contribution from any individual country.

NervAlign study approaches final recruitment

ReNerve’s central near-term clinical catalyst is the Align study of its NervAlign Nerve Cuff. The company describes a definitive study comparing standard nerve repair with repair protected by the cuff, with 120 patients planned in each cohort. The study is recruiting its final patients, with follow-up expected at roughly six to nine months and data potentially published or presented in late 2026 or early 2027.

A presentation slide compares pre- and post-surgery pain scores, showing a 54% improvement for standard care and a 95% improvement for the NervAlign-protected cohort. Those figures are presented by the company as a comparison between cohorts; the filing does not provide the statistical analysis needed to assess significance. The upcoming dataset therefore matters less as a marketing claim than as a test of whether the observed difference can withstand formal analysis and follow-up.

Pipeline extends beyond the current cuff

ReNerve says its nerve conduit and protector ranges are at Stage 3 of a four-stage FDA approval pathway, with GMP and commercial manufacturing identified as the next steps. The broader pipeline includes a nerve guide matrix, nerve cap, nerve stimulator and research programs combining nerve-repair scaffolds with platelet-rich plasma or exosomes. The company reports strong preclinical data through 12-month implants, but these programs remain at different stages of development and should not be treated as commercial products.

The company is also positioning its Empliq range of amniotic, placental and dermal allografts as an immediate commercial growth engine, alongside the longer-dated nerve portfolio. That creates a useful tension in the story: sales are already moving, but the larger product opportunity depends on execution across manufacturing, regulatory progression, clinical evidence and a costly direct-sales build-out.